Glenmark initiates myeloma drug trial

December 08, 2017 | Friday | News

GBR 1342 is an investigational new drug from the company's immuno-oncology portfolio.

Image credit- covance blog

Image credit- covance blog

Glenmark Pharma has initiated the phase-1 clinical trial of GBR 1342, an investigational antibody for treatment of multiple myeloma.

GBR 1342 is an investigational new drug from the company's immuno-oncology portfolio.

Glenmark had received clearance from US health regulator in May this year, for the investigational new drug application to initiate phase-1 study of GBR 1342.

This first-in-human, open-label study's primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached.

The additional study objectives include assessment of biomarkers, immunogenicity and additional measures of anti- tumour activity.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy